Pharma BD Deal Intelligence
King's $1.6B pain-franchise bet on Alpharma was gutted by an FTC-forced divestiture, a failed flagship product, and King itself being swallowed by Pfizer within two years.
Full analysis, sources & comparables →FTC consent order settled charges that King's $1.6B Alpharma acquisition would be anticompetitive in branded oral long-acting morphine sulfate without Kadian…
FTC required King to divest Kadian to Actavis for $127.5M because King's Avinza and Alpharma's Kadian were the only competitively significant branded morphine…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$37/share cash; Kadian, Flector, Embeda; FTC required Kadian divestiture to Actavis
King's $1.6B pain-franchise bet on Alpharma was gutted by an FTC-forced divestiture, a failed flagship product, and King itself being swallowed by Pfizer within two years.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| King Pharmaceuticals, Inc. / Alpharma Inc. (this deal) | 2008 | $1.6B | 28 |
| ViroPharma Incorporated / Lev Pharmaceuticals, Inc. | 2008 | $443M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Alkermes plc / Cephalon, Inc. (Vivitrol rights) | 2008 | $27M | 83 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
← Browse all deals · How we score deals
More: 2008 deals